Compare Rush Street Interactive Inc (RSI) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rush Street Interactive Inc vs TransMedics Group Inc — how do they compare? Rush Street Interactive Inc trades at $18.99 (market cap $2.35B), while TransMedics Group Inc trades at $78.15 (market cap $2.74B). The key difference: TransMedics Group Inc is the larger of the two by market cap, and TransMedics Group Inc is more actively traded (949,331 versus 2,219,374). Which is the better fit depends on your goals — on Pluang, investors hold Rush Street Interactive Inc for 13 Days and TransMedics Group Inc for 24 Days on average.
| RSI | TMDX | |
|---|---|---|
Market Cap | $2.35B | $2.74B |
Volume | 2,219,374 | 949,331 |
Sector | Consumer Cyclical | Health |
52-Week High | $34.52 | $150.42 |
52-Week Low | $15.89 | $61.99 |
Typical Hold Time | 13 Days | 24 Days |
Enterprise Value | $2.01B | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RSI trades at $19.32, down 4.55% today, with bearish technical signals from moving averages but neutral oscillators. The company reported mixed quarterly earnings, beating in Q1 and Q2 2026 but missing in Q4 2025. Revenue grew to $1.13B in 2025 with a net income margin of 2.33%, though profitability faces pressure as margins are expected to compress slightly in 2026. Analyst sentiment remains strongly positive with a consensus price target of $34.88, representing significant upside potential from current levels.
The stock presents a compelling opportunity given the substantial analyst upside target, but faces near-term headwinds from technical weakness and margin compression. Key risks include competitive pressures in online gaming and execution challenges in maintaining growth momentum. Institutional buying activity, including BlackRock's $448M investment in August 2026, provides confidence in the long-term thesis despite current price volatility.
TransMedics Group (TMDX) trades at $78.17, down 3.58% on the day, with a bearish technical signal and mixed earnings history. The company reported strong 2025 results with $605.49M revenue and $190.29M net income, but 2026 projections show margin compression. Recent news highlights insider buying and leadership changes alongside legal investigations into fiduciary duties, creating a complex sentiment backdrop.
The stock offers growth potential with a consensus price target of $99.75, but faces risks from earnings misses, margin pressure, and ongoing legal scrutiny. Analyst consensus remains bullish with 69% buy ratings, yet investors must weigh robust profitability metrics against execution and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Rush Street Interactive Inc
Rush Street Interactive, Inc. is a digital gaming and sports betting company operating in the regulated U.S. and international markets. The company owns and operates online casino (iGaming) and sports wagering platforms, including BetRivers and PlaySugarHouse brands. RSI focuses on providing a secure and high-quality online gaming experience, leveraging its proprietary technology platform and commitment to responsible gaming.
Read more on RSI →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
